| Title |
Author |
Type |
Date |
Words |
| Musculoskeletal Network Features New Research into the Cause of Rheumatoid Arthritis and Lupus. |
|
|
Mar 25, 2013 |
630 |
| Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drug's Limited Post-Marketing Experience and Risks of Infection and Malignancy. |
|
|
Mar 25, 2013 |
701 |
| Diversified Pipeline and Low Threat of Biosimilar Sales Erosion To Drive Growth Of Monoclonal Antibodies Market. |
|
|
Mar 19, 2013 |
1085 |
| Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion. |
|
|
Mar 4, 2013 |
2652 |
| Research and Markets: Orencia (Rheumatoid Arthritis) Forecast and Market Analysis 2012-2022: A Very Dynamic Market Following FDA Approval of Pfizer's Xeljanz. |
|
|
Jan 30, 2013 |
427 |
| Research and Markets: Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis 2012-2022. |
|
|
Jan 30, 2013 |
393 |
| Important development in diagnosis of Rheumatoid Arthritis. |
|
|
Jan 29, 2013 |
775 |
| Important development in diagnosis of Rheumatoid Arthritis. |
|
|
Jan 29, 2013 |
783 |
| Research and Markets: PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update. |
|
|
Jan 29, 2013 |
443 |
| Proof of Concept Study Initial Findings. |
|
|
Jan 28, 2013 |
609 |
| Proof of Concept Study Initial Findings. |
|
|
Jan 28, 2013 |
644 |
| New drug target for rheumatoid arthritis identified. |
|
|
Jan 26, 2013 |
670 |
| Lipophilic stinging nettle extracts possess potent anti-inflammatory activity, are not cytotoxic and may be superior to traditional tinctures for treating inflammatory disorders. |
Johnsona, Tyler A.; Sohna, Johann; Inman, Wayne D.; Bjeldanesa, Leonard F.; Rayburn, Keith |
Report |
Jan 15, 2013 |
3598 |
| HUNT FOR GIRLS WHO CAN'T CRY. |
|
|
Jan 14, 2013 |
361 |
| PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update. |
|
|
Jan 8, 2013 |
1879 |
| Research and Markets: Pfizer's tofacitinib - JAK inhibition -a new rheumatoid arthritis therapy paradigm. |
|
|
Jan 7, 2013 |
256 |
| President Barack Obama Bestows NYU Langone Medical Center's Jan Vilcek, MD, PhD, with the National Medal of Technology And Innovation. |
|
Company overview |
Jan 7, 2013 |
996 |
| QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics Through Agreements for Promising New Biomarkers. |
|
|
Jan 7, 2013 |
1942 |
| Safeguard Scientifics Co-Leads $28M Series D for Crescendo Bioscience. |
|
|
Jan 3, 2013 |
1101 |
| Leading Dermatologist Michael P. Heffernan, M.D. and Renowned Rheumatologist Alisa E. Koch, M.D. Join Lilly Autoimmune Team. |
|
|
Jan 3, 2013 |
1285 |
| Cauliflower the head of the cruciferous vegetable family. |
Gamonski, William |
Report |
Jan 1, 2013 |
1820 |
| Belgium,Japan : Astellas and UCB announce approval of Cimzia (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis. |
|
|
Dec 26, 2012 |
446 |
| Mayo Clinic Health Letter, December 2012 Highlights: Reducing the Risk of Disability from Rheumatoid Arthritis; Basic Remedies for Tongue Problems; Causes of Swollen Legs. |
|
|
Dec 19, 2012 |
1377 |
| Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch in Rheumatoid Arthritis, It Remains a Second-Line Therapy after TNF Inhibitors According to a Recent BioTrends Report. |
|
|
Dec 17, 2012 |
542 |
| Antares Pharma Announces Submission of New Drug Application for OTREXUP[TM]. |
|
|
Dec 17, 2012 |
1377 |
| In the U.S., Approximately 80 Percent of Current Prescribers of Remicade and/or Rituxan Indicate They Would Prescribe Biosimilar Versions of These Agents Within a Year of Their Approval for Rheumatoid Arthritis. |
|
|
Dec 17, 2012 |
655 |
| AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis. |
|
|
Dec 13, 2012 |
1463 |
| Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab. |
|
|
Dec 13, 2012 |
949 |
| LILLY (ELI) & COMPANY - Tabalumab RA Study BCDM Discontinuation. |
|
|
Dec 13, 2012 |
963 |
| UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community. |
|
|
Dec 11, 2012 |
1268 |
| Biologic Agents are Being Used Earlier and More Often to Treat Rheumatoid Arthritis in the EU5, According to Two Recent Reports from BioTrends. |
|
|
Dec 6, 2012 |
635 |
| By Year-End 2015, Surveyed European Rheumatologists Anticipate That the Launches of Biosimilar Etanercept and Infliximab Will Sustain Total Patient Shares of These Molecules at the Expense of Humira in the Rheumatoid Arthritis Drug Market. |
|
|
Dec 5, 2012 |
740 |
| Study Finds High-dose Intravenous Vitamin C Reduces Pain and Inflammation in Those with Rheumatoid Arthritis as Reported in a Recent Paper Published by Riordan Clinic Scientists. |
|
|
Dec 5, 2012 |
659 |
| New rheumatoid arthritis drug targets NIH-discovered protein. |
|
Brief article |
Dec 4, 2012 |
131 |
| Risk of rheumatoid arthritis with elevated rheumatoid factor. |
|
|
Dec 1, 2012 |
410 |
| Flake-shaped rice bodies. |
Kichari, J.R.; Bezooijen, R. |
Clinical report |
Dec 1, 2012 |
604 |
| The low prevalence of rheumatoid arthritis in two regions of Serbia based on evidence-based data / Kanita dayali verilere gore sirbistan'in iki bolgesinde romatoid artritin dusuk prevalansi. |
Stojanovic, Roksanda; Jovicevic, Radmila; Glogovac, Branka; Radosavljevic, Natasa; Svenda, Mirjana Z |
Clinical report |
Dec 1, 2012 |
3106 |
| A possible relationship between polymorphisms of glutathione S-transferase M1, P1 and T1 genes and rheumatoid arthritis in Zahedan, Southeast Iran / Guneydogu Iran Zahedan'da glutation S-transferaz M1, P1 ve T1 genlerinin polimorfizmlerive romatoid artrit arasindaki muhtemel iliski. |
Hashemi, Mohammad; Eskandari-Nasab, Ebrahim; Zakeri, Zahra; Atabaki, Mahdi; Rezaei, Hamzeh; Bahari, |
Report |
Dec 1, 2012 |
2472 |
| Protalex, Inc. Announces Dosing Of First Patient In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis. |
|
Clinical report |
Nov 29, 2012 |
688 |
| 'Walking on marbles' to soon become thing of past for arthritis patients. |
|
|
Nov 28, 2012 |
473 |
| Tofacitinib approved for rheumatoid arthritis. |
Mechcatie, Elizabeth |
|
Nov 15, 2012 |
550 |
| Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis. |
|
|
Nov 15, 2012 |
427 |
| Blood marker can help diagnose Rheumatoid Arthritis; New data at the 2012 Annual Meeting of the American College of Rheumatology. |
|
|
Nov 14, 2012 |
628 |
| Antares Pharma Announces Positive Results from Final MTX Medi-Jet[TM] Clinical Study. |
|
Clinical report |
Nov 13, 2012 |
1078 |
| RAPID(TM)-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis. |
|
|
Nov 13, 2012 |
5763 |
| UCB Announces Data on Cimzia (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American College of Rheumatology 2012 Congress. |
|
Clinical report |
Nov 13, 2012 |
4570 |
| Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting. |
|
|
Nov 12, 2012 |
3020 |
| Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis. |
|
|
Nov 12, 2012 |
2994 |
| New Head-to-Head Patient Reported Outcomes Data for Orencia [R] SC (abatacept) vs. Humira[R] (adalimumab) Presented at the 2012 American College of Rheumatology Annual Scientific Meeting. |
|
|
Nov 12, 2012 |
1991 |
| Infinity Reports Phase 1 Data for IPI-145 at ACR/ARHP Supporting Development in Inflammatory Conditions. |
|
|
Nov 12, 2012 |
1339 |
| SetPoint Medical Presents Positive Clinical Results for First Human Study of Implantable Neuromodulation Device for Rheumatoid Arthritis. |
|
Clinical report |
Nov 12, 2012 |
640 |
| Abbott Announces Results of Analysis Exploring the Use of HUMIRA (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis. |
|
Financial report |
Nov 12, 2012 |
1840 |
| Abbott Announces Results of Analysis Exploring the Use of HUMIRA (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis. |
|
Financial report |
Nov 12, 2012 |
1847 |
| ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy. |
|
|
Nov 10, 2012 |
1534 |
| Research and Markets: Global Rheumatoid Arthritis Drug Pipeline Capsule - 2012 Update Provides Information on Pipeline Molecules Developed In Leading Geographies. |
|
|
Nov 9, 2012 |
305 |
| MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer's XELJANZ[R] (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate. |
|
|
Nov 8, 2012 |
2230 |
| Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis. |
|
Clinical report |
Nov 8, 2012 |
686 |
| Research and Markets: Global Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2012. |
|
Clinical report |
Nov 1, 2012 |
264 |
| Legionella pneumophila serotype 1 pneumonia in patient receiving adalimumab. |
Wuerz, Terry C.; Mooney, Owen; Keynan, Yoav |
|
Nov 1, 2012 |
1662 |
| United Kingdom,United States : Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan. |
|
|
Oct 19, 2012 |
310 |
| Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan. |
|
|
Oct 18, 2012 |
935 |
| Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan. |
|
|
Oct 18, 2012 |
937 |
| Protalex, Inc. To Present Phase 1b PRTX-100 Data At The 2012 American College of Rheumatology Annual Meeting. |
|
|
Oct 18, 2012 |
730 |
| Switzerland : FDA Approves Expanded Indication for ACTEMRAA in Rheumatoid Arthritis. |
|
|
Oct 16, 2012 |
441 |
| Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to Prevent the Onset of Rheumatoid Arthritis and Potency in Treating and Reversing Bone and Cartilage Damage In Preclinical Models. |
|
|
Oct 15, 2012 |
1224 |
| Arthritis stats and figures. |
|
|
Oct 14, 2012 |
336 |
| Arthritis patient was diagnosed at just 12 months. |
|
|
Oct 14, 2012 |
509 |
| Research and Markets: Rheumatoid Arthritis - Pipeline Review, H2 2012. |
|
|
Oct 12, 2012 |
363 |
| CreakyJoints Announces "Reward Your RA Success". |
|
|
Oct 12, 2012 |
658 |
| Be aware of arthritis signs. |
|
|
Oct 12, 2012 |
302 |
| Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3? as a Testing Service in the U.S. |
|
|
Oct 9, 2012 |
559 |
| Research and Markets: Key Findings from Treatment Algorithms: Rheumatoid Arthritis - Disease-Modifying Agents. |
|
|
Oct 8, 2012 |
293 |
| 'Humanized' mice may enable discovery of better medicines for rheumatoid arthritis. |
|
|
Oct 5, 2012 |
572 |
| Subcutaneous Formulation of ORENCIA (abatacept) Approved by European Commission. |
|
|
Oct 5, 2012 |
2095 |
| Rheumatologists Continue to Prefer Enbrel and Humira as Both Their First and Second Line Biologic Agents and the Combined Formulations of Orencia as the Dominant Third Line Agent, According to a Recent BioTrends Report. |
|
|
Oct 4, 2012 |
651 |
| Research and Markets: What are European Physician and Payer Expectations for the Uptake of Emerging Oral Immunomodulators in Rheumatoid Arthritis? |
|
|
Oct 3, 2012 |
305 |
| United States : Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases. |
|
|
Oct 3, 2012 |
423 |
| Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases. |
|
|
Oct 1, 2012 |
828 |
| Research and Markets: Rheumatoid Arthritis (Event Driven). |
|
|
Sep 27, 2012 |
312 |
| Antares Pharma Announces Successful Results from VIBEX MTX Actual Human Use Study. |
|
Clinical report |
Sep 25, 2012 |
1308 |
| Although Biologic Therapy Continues to be Effective for Rheumatoid Arthritis Patients, Tofacitinib May Alter the Treatment Paradigm. |
|
|
Sep 24, 2012 |
638 |
| Janssen Submits Application To FDA Requesting Approval Of SIMPONI Intravenous Formulation For Treatment Of Moderately To Severely Active Rheumatoid Arthritis. |
|
|
Sep 18, 2012 |
2753 |
| Pfizer Announces Data For Investigational Compound Tofacitinib In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2012 Annual Meeting. |
|
|
Sep 17, 2012 |
2216 |
| The Rheumatoid Arthritis Drug Market Will Experience Modest Growth as Sales Increase from $11.1 Billion in 2011 to $15.2 Billion in 2021. |
|
|
Sep 13, 2012 |
622 |
| Japan : Eisai announces launch of anti-rheumatic agent careram. |
|
|
Sep 12, 2012 |
385 |
| Japan : Anti-Rheumatic Agent Careram(R) established by Eisai. |
|
|
Sep 12, 2012 |
372 |
| The United States Rheumatic Diseases Therapeutics Market. |
|
|
Sep 11, 2012 |
350 |
| Eisai Announces Launch of Anti-Rheumatic Agent Careram(R). |
|
|
Sep 11, 2012 |
534 |
| Zalicus Reports Top Line Phase 2b Trial Results with Synavive in Rheumatoid Arthritis. |
|
|
Sep 10, 2012 |
845 |
| 'Nobody had actually said to me that I was about to spend the rest of my life in a wheelchair, but it was becoming obvious'. |
|
|
Sep 10, 2012 |
371 |
| Research and Markets: The United States Rheumatic Diseases Therapeutics Market: Changes on the Horizon with Novel Oral Therapies for Musculoskeletal Indications. |
|
|
Sep 7, 2012 |
445 |
| Raised antibody levels in blood linked to greater risk of rheumatoid arthritis. |
|
|
Sep 7, 2012 |
431 |
| United Kingdom : GSK launches dosing in Phase III rheumatoid arthritis program jointly with JANSSEN. |
|
Clinical report |
Sep 7, 2012 |
347 |
| Cardiovascular events halved in anti-TNF users with RA. |
Zoler, Mitchel L. |
|
Sep 1, 2012 |
672 |
| From pathology to diagnosis: a symptom-free patient with a rheumatoid nodule in the foot / patolojiden taniya: semptomsuz bir hastada ayakta romatoid nodul. |
Tastekin, Ebru; Btrtane, Murat; Kilinc, Serdar; Ciftdemtr, Mert; Usta, Ufuk; Tastekin, Nurettin |
Report |
Sep 1, 2012 |
2250 |
| Posterior interosseous nerve entrapment in a patient with rheumatoid arthritis / Romatoid artritli bir hastada posterior interosseoz sinir tuzaklanmasi. |
Baklaci, Korhan; Ozgul, Ahmet |
|
Sep 1, 2012 |
2345 |
| Surveyed Rheumatoid Arthritis Patients on Biologic Therapy Believe That the Benefits Outweigh the Risks for Available Biologics, with Enbrel Rating the Highest, According to a Recent BioTrends Report. |
|
|
Aug 30, 2012 |
557 |
| Protalex, Inc. Completes Analysis of Data from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis. |
|
|
Aug 29, 2012 |
1039 |
| Ireland : PHASE 3 PROGRAM of SIRUKUMAB started by JANSSEN BIOLOGICS. |
|
|
Aug 27, 2012 |
315 |
| Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis. |
|
|
Aug 23, 2012 |
586 |
| Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis. |
|
|
Aug 23, 2012 |
578 |
| U.S. Food And Drug Administration Extends Action Date For Tofacitinib New Drug Application By Three Months. |
|
|
Aug 21, 2012 |
1184 |
| Abbott Japan and Eisai Receive Approval to Market the Fully Human Anti-TNF-Alpha Monoclonal Antibody Humira(R). |
|
|
Aug 10, 2012 |
661 |
| New 'smart' drug uses patients' own body to beat arthritis. |
|
|
Aug 9, 2012 |
362 |
| Safely manage joint inflammation: curcumin. |
Evans, Susan |
Report |
Aug 1, 2012 |
5087 |
| A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. |
|
Brief article |
Aug 1, 2012 |
200 |
| Curcumin protects human chondrocytes from IL-I1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. |
|
|
Aug 1, 2012 |
262 |
| Early data find no adalimumab teratogenicity. |
MeChcatie, Elizabeth |
Clinical report |
Aug 1, 2012 |
585 |
| Biomarkers and genes predictive of disease predisposition and prognosis in rheumatoid arthritis: rheumatoid arthritis is a debilitating disease which often progresses to relentlessly severe disease. |
Meyer, Pieter W.A. |
|
Aug 1, 2012 |
3133 |
| Septic arthritis due to Kingella kingae in an adult patient. |
Sanghvi, Ajay; Addidle, Michael; Grimwade, Kate |
Case study |
Aug 1, 2012 |
1905 |
| Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis. |
|
|
Jul 31, 2012 |
1122 |
| Abbott's HUMIRA (adalimumab) Approved in Europe for Treatment of Non-radiographic Axial Spondyloarthritis (nr-axSpA). |
|
|
Jul 30, 2012 |
1196 |
| BioTrends Research Group Has Published Its First Ever Report on Rheumatoid Arthritis from Patients' Perspectives in the UK, Germany, Italy and Spain. |
|
|
Jul 30, 2012 |
629 |
| Genentech Reports Second Positive Study of ACTEMRA[R] Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis. |
|
|
Jul 27, 2012 |
1314 |
| Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis. |
|
|
Jul 26, 2012 |
699 |
| Pharmspective Releases New Pipeline Perspectives Reports in Key Autoimmune Diseases. |
|
|
Jul 25, 2012 |
847 |
| Moderate drinking lowers risk of rheumatoid arthritis in women. |
|
|
Jul 18, 2012 |
514 |
| Research and Markets: United States Market for Rheumatoid Arthritis Pharmacotherapeutics. |
|
|
Jul 16, 2012 |
234 |
| Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance. |
Lu, Yue; Xiao, Juan; Wu, Zai-Wang; Wang, Zhe-Ming; Hu, Jia; Fu, Hong-Zheng; Chen, Ying-Yu; Qian, Rui |
Report |
Jul 15, 2012 |
5714 |
| Stricken golf star gets a 'miracle' second chance. |
|
|
Jul 12, 2012 |
602 |
| 3 drinks per week reduces risk of developing arthritis by 50pc. |
|
|
Jul 11, 2012 |
514 |
| Research and Markets: United States Market for Ankylosing Spondylitis Pharmacotherapy. |
|
|
Jul 11, 2012 |
538 |
| Enbrel and Humira Continue to Be Used as the Preferred First and Second Line Biologic Agents to Treat Rheumatoid Arthritis, but Orencia SC's Usage Has Increased over the Last Six Months. |
|
|
Jul 10, 2012 |
649 |
| Research and Markets: Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review, H1, 2012. |
|
|
Jul 3, 2012 |
369 |
| Rheumatoid arthritis can lead to unemployment and early death. |
|
|
Jul 2, 2012 |
516 |
| Chelsea Therapeutics Reports on Phase II CH-4051 For Arthritis. |
|
Clinical report |
Jul 1, 2012 |
484 |
| ChemoCentryx Reports Positive Phase 2 Data with CCX354,. |
|
|
Jul 1, 2012 |
861 |
| Halt the auto-immune attack of arthritis. |
Downey, Michael |
Report |
Jul 1, 2012 |
4826 |
| The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. |
|
|
Jul 1, 2012 |
433 |
| Effects of oral administration of type II collagen on rheumatoid arthritis. |
|
Brief article |
Jul 1, 2012 |
135 |
| Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. |
|
Author abstract |
Jul 1, 2012 |
332 |
| Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. |
|
|
Jul 1, 2012 |
352 |
| A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. |
|
Author abstract |
Jul 1, 2012 |
408 |
| Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. |
|
|
Jul 1, 2012 |
337 |
| New rheumatoid arthritis definition hangs on three joints. |
Zoler, Mitchel L. |
Disease/Disorder overview |
Jul 1, 2012 |
536 |
| Concentration of Nitric Oxide in saliva of patients with rheumatoid arthritis. |
Dervisevic, Amela; Babic, Nermina; Huskic, Jasminko; Sokolovic, Sekib; Nakas-Icindic, Emina; Causevi |
Report |
Jul 1, 2012 |
3417 |
| MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. |
Pincus, Theodore; Skummer, Philip T.; Grisanti, Michael T.; Castrejon, Isabel; Yazici, Yusuf |
|
Jul 1, 2012 |
5070 |
| Predictors of response to TNF inhibitors in rheumatoid arthritis: do we have new tools for personalized medicine? |
Simsek, Ismail |
|
Jul 1, 2012 |
2842 |
| T-cell agents in the treatment of rheumatoid arthritis: 2012 update. |
Solomon, Gary E. |
|
Jul 1, 2012 |
2643 |
| IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. |
Woodrick, Robert S.; Ruderman, Eric M. |
|
Jul 1, 2012 |
3587 |
| B-cell therapies for rheumatoid arthritis. |
Scher, Jose U. |
|
Jul 1, 2012 |
2975 |
| Kinase inhibitors for the treatment of rheumatoid arthritis. |
Yazici, Yusuf; Steiger, Benjamin |
|
Jul 1, 2012 |
3497 |
| Heavy snorers at 'double risk' of rheumatoid arthritis. |
|
|
Jun 29, 2012 |
528 |
| Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan. |
|
|
Jun 29, 2012 |
470 |
| Research and Markets: Sjogren's Syndrome Global Clinical Trials Review, H1, 2012. |
|
|
Jun 28, 2012 |
351 |
| Programme launched for early detection of rheumatoid arthritis. |
|
|
Jun 28, 2012 |
409 |
| Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 Development in Inflammation. |
|
|
Jun 27, 2012 |
1433 |
| Antares Pharma Announces Positive Results from VIBEX MTX Usability Study. |
|
Report |
Jun 26, 2012 |
703 |
| Study Validates Use of Crescendo Bioscience's Vectra[TM] DA Test as an Objective Measure of Rheumatoid Arthritis Disease Activity. |
|
|
Jun 26, 2012 |
1076 |
| Abbott Receives Positive Opinion for HUMIRA in Non-radiographic Axial Spondyloarthritis from EMA's CHMP. |
|
|
Jun 25, 2012 |
1079 |
| New arthritis programme sees ME launch. |
|
|
Jun 24, 2012 |
630 |
| Research and Markets: The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst. |
|
|
Jun 22, 2012 |
352 |
| The Use of Biologics for Rheumatoid Arthritis in China is Limited to the Biosimilar Yi Sai Pu and Branded Etanercept, According to a Recent BioTrends Report. |
|
|
Jun 21, 2012 |
577 |
| Questcor Announces Initial Commercialization Plans for Acthar Rheumatology Indications. |
|
|
Jun 14, 2012 |
1866 |
| Illness hits patients and their families; Grant may help arthritis sufferers and loved ones. |
|
|
Jun 13, 2012 |
608 |
| Changes in gut bacteria may trigger diseases like rheumatoid arthritis. |
|
|
Jun 12, 2012 |
675 |
| Research centre gives hope to arthritis patients. |
|
|
Jun 11, 2012 |
340 |
| ARTHRITIS TRIAL HOPE. |
|
|
Jun 9, 2012 |
242 |
| HOPE ON ARTHRITIS; New treatment hailed the best at relieving symptoms. |
|
|
Jun 8, 2012 |
229 |
| Arthritis sufferers in new treatment hope; Drug trialled on Tyneside 'more likely to halt progression'. |
|
|
Jun 8, 2012 |
409 |
| Post Hoc Analysis Indicated That Timing And Magnitude Of Initial Response To Certolizumab Pegol Predicted Likelihood Of Low Disease Activity At Week 28 In Patients With Active Moderate To Severe Rheumatoid Arthritis. |
|
Clinical report |
Jun 8, 2012 |
3987 |
| Research and Markets: Sjogren's Syndrome - Pipeline Review, H1 2012. |
|
|
Jun 7, 2012 |
455 |
| ORENCIA[R] (abatacept) Demonstrates Comparable Efficacy to Humira[R] (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents. |
|
|
Jun 6, 2012 |
2218 |
| Arthritis treatment 'too little, too late' Patients are 'left until they are disabled'. |
|
|
Jun 6, 2012 |
461 |
| Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA (Adalimumab) in Patients with Active Peripheral Spondyloarthritis. |
|
Clinical report |
Jun 6, 2012 |
1440 |
| RAPID(TM)-PsA study showed that certolizumab pegol improved the signs and symptoms of psoriatic arthritis. |
|
|
Jun 6, 2012 |
3724 |
| Abbott Announces 10-Year Data Evaluating HUMIRA (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis. |
|
Clinical report |
Jun 6, 2012 |
1807 |
| ORENCIA ,u- (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents. |
|
|
Jun 6, 2012 |
2042 |
| Abbott Announces 10-Year Data Evaluating HUMIRA (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis. |
|
Clinical report |
Jun 6, 2012 |
1809 |
| New Phase 3 Data Show SIMPONI Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease. |
|
|
Jun 5, 2012 |
3096 |
| Crescendo Bioscience's Vectra[TM] DA Test Indicates Remission in Rheumatoid Arthritis Patients. |
|
|
Jun 5, 2012 |
2024 |
| Genentech's ACTEMRA[R] Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab as Single-Agent Therapy. |
|
|
Jun 5, 2012 |
1582 |
| UCB to showcase broad immunology portfolio at EULAR 2012. |
|
|
Jun 1, 2012 |
4434 |
| BCM-95 curcumin as effective as prescription drug in rheumatoid arthritis. |
|
Clinical report |
Jun 1, 2012 |
194 |
| Follow-up results of our patients with rheumatoid arthritis / romatoid artritli hastalarimizin takip sonuclari. |
Yalcin, Tugba; Bal, Ajda; Dulgeroglu, Deniz; Cakci, Aytul |
Report |
Jun 1, 2012 |
6263 |
| Validation of the Personal Impact Health Assessment Questionnaire in patients with rheumatoid arthritis in Kerman, Iran / Iran Kerman'da romatoid artrit hastalarinda Kisisel Saglik Degerlendirme Anketi'nin dogrulanmasi. |
Shakibi, Mohammad Reza; Zolala, Farzaneh; Monshi, Mahdookht; Hghdoost, Ali Akbar |
Survey |
Jun 1, 2012 |
3710 |
| A lytic lesion on the head of the fifth metatarsal bone mimicking rheumatoid arthritis in a geriatric patient / geriatrik bir olguda besinci metatars basinda romatoid artriti taklit eden litik lezyon. |
Isik, Metin |
|
Jun 1, 2012 |
497 |
| Surveyed U.S. Rheumatologists and MCO Pharmacy Directors Agree That a Drug's Effect on the Signs and Symptoms of Rheumatoid Arthritis is One of the Attributes That Most Influences Their Decisions Regarding Prescribing and Formulary Status. |
|
|
May 31, 2012 |
624 |
| Six Months Post-Launch, Trial and Usage of Orencia SC is Continuing to Increase, Yet It is Still Viewed as a Second-Line Therapy After Anti-TNF Agents for Rheumatoid Arthritis Based on a Recent BioTrends Report. |
|
|
May 30, 2012 |
695 |
| Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA (Adalimumab) at the Annual Meeting of the European League Against Rheumatism. |
|
|
May 29, 2012 |
1882 |
| VQ OrthoCare[R] Announces New Treatment Option for Rheumatoid Arthritis. |
|
|
May 24, 2012 |
541 |
| New target to battle rheumatoid arthritis identified. |
|
|
May 21, 2012 |
589 |
| Research and Markets: Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2012. |
|
Report |
May 16, 2012 |
461 |
| Panel recommends tofacitinib approval for refractory RA. |
Tucker, Miriam E. |
|
May 15, 2012 |
708 |
| Bristol-Myers Squibb to Present New Data on ORENCIA(R),u- (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress. |
|
Clinical report |
May 14, 2012 |
1217 |
| FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis. |
|
|
May 9, 2012 |
863 |
| Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection. |
|
|
May 3, 2012 |
1010 |
| Anemia triples infection risk with biologics. |
London, Susan |
|
May 1, 2012 |
601 |
| Zalicus Completes Patient Enrollment in Phase 2b Clinical Trial of Synavive in Rheumatoid Arthritis. |
|
|
Apr 30, 2012 |
901 |
| Research and Markets: Global Rheumatoid Arthritis Drugs Market 2011-2015 - The Global Rheumatoid Arthritis Drugs Market to Grow At A CAGR Of 12.1 Percent over the Period 2011-2015. |
|
|
Apr 13, 2012 |
366 |
| New classification criteria released for research on Sjogren's Syndrome. |
|
|
Apr 11, 2012 |
118 |
| My hands are gnarly and painful, but I won't let arthritis take over; FIVE PAGES OF HEALTH, BEAUTY AND LIFESTYLE SCOTS TELLY STAR AGGIE MACKENZIE IS DETERMINED ILL HEALTH WILL NOT WIN. |
|
|
Apr 3, 2012 |
938 |
| RA autoimmunity may smolder in the lungs. |
Jancin, Bruce |
|
Apr 1, 2012 |
569 |
| Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastic therapy. |
Alias, Abie; Rodriguez, Ernesto J.; Bateman, Helen E.; Sterrett, Ashley G.; Valeriano-Marcet, Joanne |
Disease/Disorder overview |
Apr 1, 2012 |
4110 |
| An evidence-based medical visit for patients with rheumatoid arthritis based on standard, quantitative scientific data from a patient MDHAQ and physician report. |
Pincus, Theodore; Castrejon, Isabel |
Report |
Apr 1, 2012 |
9164 |
| Endosymbiotic actinidic archaea and viroids-role in immune regulation. |
Ravikumar, Kurup A.; Kurup, Parameswara Achutha |
Report |
Mar 31, 2012 |
3288 |
| Research and Markets: Disease Modification in Rheumatoid Arthritis - Game-changing Therapy Close to Market. |
|
|
Mar 29, 2012 |
519 |
| Rheumatologists Continue to Increase Their Use of Biologics for the Treatment of RA Compared to a Year Ago, but Areas of Improvement Exist for This Drug Class. |
|
|
Mar 28, 2012 |
544 |
| Research and Markets: Rheumatoid Arthritis - Pipeline Review, H1 2012. |
|
|
Mar 27, 2012 |
432 |
| Atrial fibrillation, stroke risks elevated in RA. |
Splete, Heidi |
|
Mar 15, 2012 |
551 |
| Rheumatoid arthritis ups risk of irregular heart rhythm and stroke. |
|
|
Mar 9, 2012 |
341 |
| Arthritis sufferers offered new hope; Breakthrough set to go to clinical trials. |
|
|
Mar 6, 2012 |
598 |
| Genentech's ACTEMRA[R] Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy. |
|
|
Mar 2, 2012 |
1296 |
| Sjogren's syndrome presenting with epileptic seizure/Ilk bulgusu epilepsi nobeti olan primer Sjogren sendromu. |
Koc, Emine Rabia; Duzgun, Ulkuhan; Ersoy, Alevtina; Ilhan, Atilla |
Case study |
Mar 1, 2012 |
1149 |
| Arthritis pattern in psoriasis guides diagnosis. |
Jancin, Bruce |
|
Mar 1, 2012 |
594 |
| Biologic users mycobacterial lung infection. |
Jancin, Bruce |
|
Mar 1, 2012 |
792 |
| TNF inhibitors did not raise risk of zoster in large study. |
Jancin, Bruce |
Clinical report |
Mar 1, 2012 |
686 |
| Using clinical and multislice computer tomographic features to assess temporomandibular joint osseous involvement in rheumatoid arthritis: a preliminary study / Romatid artritte osseoz temporomandibuler eklem tutulumunun klinik ve cok kesitli bilgisayarli tomografi ozellikleri: on calisma. |
Gheita, Tamer; Dahaba, Moushira; Ahmed, Eman; Khalifa, Shorouk; Basmy, Ayman |
Report |
Mar 1, 2012 |
5472 |
| Rheumatoid arthritis: a rare cause of cardiac tamponade / Kardiyak tamponadin nadir bir nedeni: romatoid artrit. |
Canga, Yigit; Ozcan, Kazim Serhan; Karatas, Mehmet Baran; Durmus, Gunduz; Erdinler, Izzet Celal |
Report |
Mar 1, 2012 |
1488 |
| Approval for drug after trial in North. |
|
|
Feb 22, 2012 |
253 |
| Glucocorticoid injections controlled early RA. |
Worcester, Sharon |
|
Feb 15, 2012 |
532 |
| Joint surgery growing less common in RA. |
McCall, Becky |
Clinical report |
Feb 15, 2012 |
514 |
| Rheumatoid arthritis drug halts organ damage in inflammatory genetic disorder. |
|
|
Feb 11, 2012 |
598 |
| RA, erectile dysfunction association seen. |
Wachter, Kerri |
|
Feb 1, 2012 |
236 |
| Prior glucocorticoids raise infection risk in RA. |
McCall, Becky |
|
Feb 1, 2012 |
624 |
| Benitec Biopharma, Medistem Technologies combine preclinical stem cell therapy for rheumatoid arthritis. |
|
Clinical report |
Feb 1, 2012 |
143 |
| Arthritis is too painful to enjoy life; HEALTH. |
|
|
Jan 24, 2012 |
136 |
| Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment. |
Yazici, Yusuf |
|
Jan 15, 2012 |
2294 |
| Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis: documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). |
Pincus, Theodore; Castrejon, Isabel |
Clinical report |
Jan 15, 2012 |
5423 |
| Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. |
Saag, Kenneth G. |
Clinical report |
Jan 15, 2012 |
3757 |
| A fresh look at glucocorticoids: how to use an old ally more effectively. |
Buttgereit, Frank |
|
Jan 15, 2012 |
2640 |
| Circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications. |
Haus, Erhard; Sackett-Lundeen, Linda; Smolensky, Michael H. |
Report |
Jan 15, 2012 |
4399 |
| Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. |
Pincus, Theodore; Yazici, Yusuf; Castrejon, Isabel |
Clinical report |
Jan 15, 2012 |
2948 |
| Venus Williams pulls out of Australian Open over flare up of Sjogren's syndrome. |
|
|
Jan 10, 2012 |
233 |
| RainDance Technologies Teams with Hospital Saint-Louis and BGI to Confirm Mutations Associated with Rheumatoid Arthritis. |
|
|
Jan 9, 2012 |
1016 |
| Arthritis patients need more exercise, CDC says. |
Splete, Heidi |
|
Jan 1, 2012 |
511 |
| Subcutaneous biologic for RA stacks up well. |
Schonfeld, Amy Rothman |
|
Jan 1, 2012 |
709 |
| Tocilizumab monotherapy for RA may suffice for some. |
Schonfeld, Amy Rothman |
|
Jan 1, 2012 |
783 |
| Pharmacological properties of herbal oil extracts used in Iranian traditional medicine. |
Mikaili, Peyman; Shayegh, Jalal; Sarahroodi, Shadi; Sharifi, Massoumeh |
Report |
Jan 1, 2012 |
3140 |
| Running with Sjogren's syndrome. |
Handy, Beverly C.; Handy, Dexter R. |
|
Jan 1, 2012 |
962 |
| A cholesterol and actinide dependent shadow biosphere of archaea and viroids in autoimmune diseases. |
Kurup A., Ravikumar; Kurup, Parameswara Achutha |
Report |
Dec 31, 2011 |
4090 |
| Rosehips and rheumatoid arthritis. |
Finney-Brown, Tessa |
Report |
Dec 22, 2011 |
412 |
| UCB Announces Start of the EXXELERATE(TM) Clinical Study in Rheumatoid Arthritis. |
|
Clinical report |
Dec 21, 2011 |
2968 |
| Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis. |
|
|
Dec 20, 2011 |
712 |
| Up to 58 Percent of Surveyed Rheumatologists in France, Germany, Italy and the United Kingdom Expect to Initially Prescribe Tofacitinib for Rheumatoid Arthritis Only to Patients with Normal Cholesterol Levels. |
|
|
Dec 7, 2011 |
524 |
| Gold Standard Diagnostics Launches Axis-Shield's New and Improved Anti-CCP2 Assay for Early and Accurate Diagnosis of Rheumatoid Arthritis. |
|
|
Dec 6, 2011 |
475 |
| Low-dose prednisone shores up effects of MTX-based regimens in early RA. |
Worcester, Sharon |
|
Dec 1, 2011 |
493 |
| Trial Backs Methotrexate as first Tx for early RA. |
Worcester, Sharon |
|
Dec 1, 2011 |
555 |
| RA doubles fracture risk in women. |
Wachter, Kerri |
|
Dec 1, 2011 |
436 |
| Beware of those beers. |
Greenbaum, Larry |
|
Dec 1, 2011 |
1043 |
| Editorial. |
Rheumatol, Turk J. |
Editorial |
Dec 1, 2011 |
581 |
| Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism / romatoid artritin tedavisi: Turkiye romatizma arastirma ve savas dernegi uzlasi onerileri. |
Ataman, Sebnem; Borman, Pinar; Evcik, Deniz; Aydog, Ece; Ayhan, Figen; Yildizlar, Derya; Bodur, Hati |
Report |
Dec 1, 2011 |
16674 |
| Eosinophilic gastroenteritis associated with rheumatoid arthritis / eozinofilik gastroenterit ile romatoid artrit birlikteligi. |
Paksoy, Fatma; Ulas, Turgay; Namal, Esat; Gulturk, Emine; Aydogan, Timucin; Borlu, Fatih |
Clinical report |
Dec 1, 2011 |
1570 |
| Lupus myositis with normal creatinine kinase levels following adalimumab use in a rheumatoid arthritis patient / bir romatoid artrit hastaslnda adalimumab kullanlmlnln ardlndan gelisen ve normal kreatinin kinaz seviyelerinin eslik ettigi lupus miyoziti. |
Almoallim, Hani; ALmasari, Ahlam; Khadawardi, Hadeel |
Report |
Dec 1, 2011 |
2427 |
| Bisphosphonate-related osteonecrosis of the jaw bones in a patient with ankylosing spondylitis receiving anti-tumor necrosis factor treatment / anti-tumor nekroz faktor tedavisi alan ankilozan spondilitli bir olguda gelisen bifosfonatla iliskili cene osteonekrozu. |
Isleten, Banu; Hepguler, Simin; Bayraktaroglu, Selen; Keser, Gokhan |
Report |
Dec 1, 2011 |
2464 |
| Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis. |
|
|
Nov 21, 2011 |
536 |
| BioTrends Survey of Over 1,300 Patients with Autoimmune Disorders Indicates High Disease Impact on Quality of Life Metrics and Challenges Patients Face with Their Disease. |
|
Clinical report |
Nov 21, 2011 |
478 |
| ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis. |
|
|
Nov 8, 2011 |
1407 |
| New Data From REALISTIC Study Showed Cimzia (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-TNF Therapy. |
|
|
Nov 7, 2011 |
3254 |
| Abbott Announces New Long-Term Data Evaluating Use of HUMIRA (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA. |
|
Clinical report |
Nov 6, 2011 |
1397 |
| Abbott Announces New Long-Term Data Evaluating Use of HUMIRA (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA. |
|
Clinical report |
Nov 6, 2011 |
1323 |
| Young women with rheumatoid arthritis 'at greater risk of fractures'. |
|
|
Nov 6, 2011 |
325 |
| Mayo Clinic: Young Women with Rheumatoid Arthritis at More Risk for Broken Bones. |
|
|
Nov 5, 2011 |
487 |
| Studies Show Vectra[TM] DA Multi-Biomarker Test Algorithm More Accurate Than Other Established Disease Activity Measures in Identifying Rheumatoid Arthritis Patients at Risk for Joint Damage Progression. |
|
|
Nov 5, 2011 |
2112 |
| Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis. |
|
|
Nov 5, 2011 |
1651 |
| Treatment With Enbrel (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease. |
|
|
Nov 5, 2011 |
3570 |
| Research and Markets: Rheumatoid Arthritis - Pipeline Review, H2 2011. |
|
|
Nov 4, 2011 |
434 |
| UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting. |
|
|
Nov 4, 2011 |
985 |
| The Market Share of TNF-alpha Inhibitors for the Treatment of Rheumatoid Arthritis Will Decrease from 75 Percent in 2010 to 53 Percent in 2020. |
|
|
Nov 2, 2011 |
595 |
| CareFirst BlueCross BlueShield, Cardinal Health Specialty Solutions Launch First Clinical Pathways Program for Rheumatoid Arthritis. |
|
|
Nov 1, 2011 |
1283 |
| Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases. |
|
|
Oct 27, 2011 |
1341 |
| Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting. |
|
|
Oct 27, 2011 |
1252 |
| Progenra and Tokyo Medical University Form Rheumatoid Arthritis Research Collaboration. |
|
|
Oct 24, 2011 |
429 |
| Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology. |
|
|
Oct 24, 2011 |
1565 |
| AcurianHealth Survey Reveals Rheumatoid Arthritis Community Desires New Treatment Options. |
|
Clinical report |
Oct 12, 2011 |
504 |
| Antares Pharma Granted New U.S. Patent Covering VIBEX[TM] Injector Technology. |
|
|
Oct 4, 2011 |
1211 |
| Surveyed Rheumatologists Estimate That, in 2014, 24 Percent of Rheumatoid Arthritis Patients Who Receive Tofacitinib Would Be Biologic-Naive and 30 Percent Would Have Been Treated with at Least One TNF-alpha Inhibitor. |
|
|
Oct 3, 2011 |
661 |
| Crescendo Bioscience Gets $56 Million For Diagnostics. |
|
|
Sep 30, 2011 |
629 |
| Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018. |
|
|
Sep 28, 2011 |
774 |
| The Strong Woman's Approach to Managing Rheumatoid Arthritis. |
|
|
Sep 28, 2011 |
984 |
| REPEAT/The Strong Woman's Approach to Managing Rheumatoid Arthritis. |
|
|
Sep 28, 2011 |
984 |
| Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira(R)(adalimumab), a Fully Human Anti-TNF-alpha Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis. |
|
|
Sep 26, 2011 |
634 |
| Effective herbal treatment for rheumatoid arthritis. |
Finney-Brown, Tessa |
Report |
Sep 22, 2011 |
402 |
| New 10 Pounds-a-day jab gives hope to millions of arthritis patients. |
|
|
Sep 22, 2011 |
259 |
| Rheumatoid Arthritis Market Forecast. |
|
Industry overview |
Sep 20, 2011 |
630 |
| Clinical Trial Recruitment for Autoimmune Diseases Was Highest for Rheumatoid Arthritis During 2000-2009: companiesandmarkets.com. |
|
|
Sep 16, 2011 |
442 |
| Less plaque progression in TNF inhibitor users. |
Sullivan, Michele G. |
Clinical report |
Sep 15, 2011 |
866 |
| 'The Rheumatoid Arthritis Drugs Market Generated $12.7bn in 2010' Says visiongain Report. |
|
Report |
Sep 8, 2011 |
1804 |
| Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting. |
|
|
Sep 8, 2011 |
2023 |
| Lack of 'bouncer' protein behind onset of rheumatoid arthritis. |
|
|
Sep 8, 2011 |
195 |
| Venus Williams reveals mystery illness with no known cure. |
|
|
Sep 1, 2011 |
282 |
| Subcutaneous biologic approved. |
|
|
Sep 1, 2011 |
209 |
| Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and their relationship with extra-articular manifestations/Romatoid artritte anti-siklik sitrulinli peptid antikorlar ve bunlarin ekstra-artikuler bulgular ile iliskisi. |
Ortancil, Ozgur; Bulmus, Nercivan; Ozdolap, Senay; Kiran, Sibel; Arasli, Mehmet |
Clinical report |
Sep 1, 2011 |
3183 |
| Investigation of glucocorticoid receptor gene Bcl-1 polymorphism in rheumatoid arthritis/romatoid artritte glukokortikoid reseptoru geni Bcl-1 polimorfizminin arastirilmasi. |
Aydeniz, Ali; Sever, Tugce; Pehlivan, Sacide; Pehlivan, Mustafa; Altindag, Ozlem; Budeyri, Selin; Gu |
Report |
Sep 1, 2011 |
2829 |
| Serum levels of anti-citrullinated protein antibody (ACPA) and tweak in patients with rheumatoid arthritis: association with disease activity and treatment modalities / romatoid artritli hastalarda serum TWEAK ve anti-sitrulinlenmis protein antikor (ACPA) seviyeleri: tedavi yontemleri ve hastalik aktivitesiyle iliskisi. |
Karkucak, Murat; Capkin, Erhan; Cakirbay, Hasim; Alver, Ayse; Cansu, Aysegul; Demirok, Duygu; Tosun, |
Report |
Sep 1, 2011 |
3667 |
| Fear of falling, fall risk and disability in patients with rheumatoid arthritis / romatoid artritli hastalarda dusme korkusu, dusme riski ve disabilite. |
Cakit, Burcu Duyur; Nacir, Baris; Erdem, Hatice Rana; Karagoz, Aynur; Saracoglu, Meryem |
Clinical report |
Sep 1, 2011 |
5905 |
| Blocking TNF-[alpha] in complex regional pain syndrome type I: A case of reflex sympathetic dystrophy resolved with etanercept in a patient with ankylosing spondylitis / kompleks bolgesel agri sendromu tip i'de tnf-[alpha] blokaji: Ankilozan spondilitli bir hastada gelisen ve etanersept ile iyilesen bir refleks sempatik distrofi olgusu. |
Ozgul, Ahmet; Vural, Dilek; Taskaynatan, Mehmet Ali |
Report |
Sep 1, 2011 |
2395 |
| Pleuropericarditis associated with sulphasalazine in a case of rheumatoid arthritis: a drug-induced lupus-like syndrome / romatoid artritli bir olguda sulfasalazinle iliskili ploroperikardit: ilac kaynakli lupus benzeri sendrom. |
Hiz, Ozcan; Gulcu, Elif; Ozkan, Yasemin; Tekeoglu, Ibrahim; Aladag, Nesim |
Report |
Sep 1, 2011 |
2427 |
| Coexistence of Behcet's disease and ankylosing spondylitis: behcet hastaligi ve Ankilozan spondilit birlikteligi. |
Celik, Canan; Ucan, Halil; Uckun, Asli Caliskan; Alemdaroglu, Ebru |
|
Sep 1, 2011 |
1272 |
| Defective gene behind rheumatoid arthritis identified. |
|
|
Aug 17, 2011 |
257 |
| Arthritis sufferers at increased risk of dying due to cardiovascular disease. |
|
|
Aug 15, 2011 |
236 |
| Genetic clue behind rheumatoid arthritis, autoimmune disorders identified. |
|
Disease/Disorder overview |
Aug 15, 2011 |
212 |
| The effects of rose hip (Rosa canina) on plasma antioxidative activity and C-reactive protein in patients with rheumatoid arthritis and normal controls: a prospective cohort study. |
Kirkeskov, Bente; Christensen, Robin; Bugel, Susanne; Bliddal, Henning; Danneskiold-Samsoe, Bente; P |
Report |
Aug 15, 2011 |
5878 |
| Over 40 Percent of U.S. Rheumatoid Arthritis Patients Who Have Never Taken a Biologic Drug Have Discussed the Possibility of Starting These Treatments with Their Physician According to a New Study by BioTrends Research Group. |
|
|
Aug 11, 2011 |
496 |
| Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'. |
|
|
Aug 10, 2011 |
1008 |
| Arthritis Patient Helped Create Innovative Knee Implant That Restored His Active Lifestyle. |
|
|
Aug 8, 2011 |
691 |
| Antares Pharma Announces Positive Study Results with VIBEX[TM] MTX in Rheumatoid Arthritis Patients. |
|
|
Aug 4, 2011 |
1173 |
| AB Science announces recruitment of first patient in phase 2B/3 study of masitinib in rheumatoid arthritis. |
|
Clinical report |
Aug 3, 2011 |
1017 |
| Femta Pharmaceuticals Announces IND Filing of FM101, a Novel Monoclonal Antibody Targeting IL-6 with Potent Anti-Inflammatory Activity. |
|
|
Aug 1, 2011 |
569 |
| Post-MI cardioprotection missed in RA patients. |
Freeman, Sara |
|
Aug 1, 2011 |
566 |
